Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CKD patients (defined as serum creatinine 1.5 to 6.0 mg/dL for women and 2.0 to 6.0 g/mg/dL for men)~* Stable Hb (\>= 11.0g/dL) and currently receiving PROCRIT therapy for 2 months or more. A stable Hemoglobin will be defined as a value that is ± 10% for 3 consecutive laboratory values.~Exclusion Criteria:~* Lactating or pregnant women~* Uncontrolled hypertension~* Known hypersensitivity to mammalian cell-derived products and human albumin~* Receiving dialysis or scheduled to receive dialysis during the course of the study~* gastrointestinal bleeding~* Severe Congestive Heart Failure (New York Heart Association Class IV)~* Concurrent chemotherapy for cancer~* History of/or active blood disorders, liver diseases or seizures~* HIV positive~* Received a kidney transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).